Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (581-590 of 664) with videos related to

Pageof 67
Sort By:
Disease Models & Mechanisms|May 17, 2014
A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformationHenning Sievert, Nora Pällmann, Katharine K Miller, et al.
Kidney International|February 9, 2024
Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemiaJan Czogalla, Simon Schliffke, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to CrizotinibLars-Arne Berger, Melanie Janning, Janna-Lisa Velthaus, et al.
International Journal of Cancer|May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialMarkus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Hemasphere|August 16, 2021
AXL Inhibition Represents a Novel Therapeutic Approach in <i>BCR-ABL</i> Negative Myeloproliferative NeoplasmsAntonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, et al.
Cancer Research|December 30, 2016
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> PolymorphismFriederike Braig, Malte Kriegs, Minna Voigtlaender, et al.
Cancer Cell|May 5, 2022
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT studyMartin Schönlein, Victoria Wrage, Susanne Ghandili, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Marine Drugs|March 24, 2022
Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer AgentsMaxim E Zhidkov, Moritz Kaune, Alexey V Kantemirov, et al.
American Journal of Hematology|March 31, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter AnalysisMaximilian Al-Bazaz, Winfried Alsdorf, Lisa Leypoldt, et al.
Pageof 67

Showing results (581-590 of 664) with videos related to

Sort By:
Pageof 67
Disease Models & Mechanisms|May 17, 2014
A novel mouse model for inhibition of DOHH-mediated hypusine modification reveals a crucial function in embryonic development, proliferation and oncogenic transformationHenning Sievert, Nora Pällmann, Katharine K Miller, et al.
Kidney International|February 9, 2024
Ibrutinib-associated focal segmental glomerulosclerosis and the impact of podocin mutations in chronic lymphocytic leukemiaJan Czogalla, Simon Schliffke, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2018
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to CrizotinibLars-Arne Berger, Melanie Janning, Janna-Lisa Velthaus, et al.
International Journal of Cancer|May 18, 2010
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialMarkus M Heiss, Pawel Murawa, Piotr Koralewski, et al.
Hemasphere|August 16, 2021
AXL Inhibition Represents a Novel Therapeutic Approach in <i>BCR-ABL</i> Negative Myeloproliferative NeoplasmsAntonia Beitzen-Heineke, Nikolaus Berenbrok, Jonas Waizenegger, et al.
Cancer Research|December 30, 2016
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K<sub>521</sub> PolymorphismFriederike Braig, Malte Kriegs, Minna Voigtlaender, et al.
Cancer Cell|May 5, 2022
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT studyMartin Schönlein, Victoria Wrage, Susanne Ghandili, et al.
Cancers|June 20, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsMelanie Janning, Franca Kobus, Anna Babayan, et al.
Marine Drugs|March 24, 2022
Study of Structure-Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer AgentsMaxim E Zhidkov, Moritz Kaune, Alexey V Kantemirov, et al.
American Journal of Hematology|March 31, 2026
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter AnalysisMaximilian Al-Bazaz, Winfried Alsdorf, Lisa Leypoldt, et al.
Pageof 67